The drug costs Rs. 59, 750 each and should be taken in two doses. In a joint statement, Cipla and Roche said, “The first batch of the antibody cocktail (Casirivimab and Imdevimab) is now available in india while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in india offers treatment for two patients.”

An antibody cocktail helps to fight against the infection by enacting as human antibodies. The release mentioned that the Central drugs Standards Control Organisation had recently provided an emergency use authorisation for the antibody cocktail in India.

Cipla Managing director and Chief Executive Officer Umang Vohra tweeted about the same on monday that read, “Hoping this antibody cocktail casirivimab and imdevimab provides the much needed relief to patients and healthcare system in India.”